• #952614
  • 1,181
  • Merck #00006412102

Gardasil® 9 Human Papillomavirus Vaccine (HPV) For Females 9 through 45 Years of Age / Males 9 through 45 Years of Age 20 mcg - 60 mcg / 0.5 mL Injection Prefilled Syringe Intramuscular

GARDASIL 9 HPV VACC, SYR 0.5ML(10/BX) MRKVAC

Features
  • GARDASIL 9 is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
  • Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein
  • Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months
  • More …
Container Type
Prefilled Syringe Single Dose Vial
  Log In to Order
or

Professionals Also Viewed


Product Specifications


McKesson #952614
Manufacturer #00006412102
BrandGardasil® 9
ManufacturerMerck
Country of OriginUnited States
ApplicationHuman Papillomavirus Vaccine (HPV)
Container TypePrefilled Syringe
Dosage FormInjection
Generic Drug Code37568
Generic Drug NameHuman Papillomavirus 9-Valent Vaccine, Recombinant, Preservative Free
NDC Number00006-4121-02
Product DatingMcKesson Acceptable Dating: we will ship >= 180 days
Storage RequirementsRequires Refrigeration
Strength20 mcg - 60 mcg / 0.5 mL
TypeIntramuscular
UNSPSC Code51201649
UserFor Females 9 through 45 Years of Age / Males 9 through 45 Years of Age
Volume0.5 mL
Features
  • GARDASIL 9 is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
  • Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein
  • Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months
  • Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58